Technical Analysis for IMM - Immutep Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Fell Below 20 DMA | Bearish | 7.02% | |
| MACD Bearish Centerline Cross | Bearish | 7.02% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Crossed Above 50 DMA | Bullish | -4.69% | |
| Calm After Storm | Range Contraction | -4.69% | |
| Fell Below 50 DMA | Bearish | -3.17% | |
| Upper Bollinger Band Walk | Strength | -3.17% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 1 day ago |
| Up 1 ATR | 1 day ago |
| Rose Above 20 DMA | 1 day ago |
| Up 5% | 1 day ago |
| Gap Up Partially Closed | 1 day ago |
Get this analysis on your stocks daily!
Immutep Limited Description
Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Biotechnology Cancer Therapy Therapeutic Product Breast Cancer Therapeutic Products Biomed Cancer Immunotherapy Melanoma Immunotherapeutic Products Medical Biotechnology Metastatic Breast Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.485 |
| 52 Week Low | 0.23 |
| Average Volume | 4,716,169 |
| 200-Day Moving Average | 0.361 |
| 50-Day Moving Average | 0.313 |
| 20-Day Moving Average | 0.299 |
| 10-Day Moving Average | 0.314 |
| Average True Range | 0.018 |
| RSI (14) | 49.24 |
| ADX | 18.86 |
| +DI | 20.736 |
| -DI | 19.249 |
| Chandelier Exit (Long, 3 ATRs) | 0.295 |
| Chandelier Exit (Short, 3 ATRs) | 0.325 |
| Upper Bollinger Bands | 0.336 |
| Lower Bollinger Band | 0.262 |
| Percent B (%b) | 0.58 |
| BandWidth | 24.658 |
| MACD Line | -0.001 |
| MACD Signal Line | -0.002 |
| MACD Histogram | 0.0013 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.335 | ||||
| Resistance 3 (R3) | 0.333 | 0.322 | 0.330 | ||
| Resistance 2 (R2) | 0.322 | 0.314 | 0.323 | 0.328 | |
| Resistance 1 (R1) | 0.313 | 0.309 | 0.318 | 0.315 | 0.327 |
| Pivot Point | 0.302 | 0.302 | 0.304 | 0.303 | 0.302 |
| Support 1 (S1) | 0.293 | 0.294 | 0.298 | 0.295 | 0.283 |
| Support 2 (S2) | 0.282 | 0.289 | 0.283 | 0.282 | |
| Support 3 (S3) | 0.273 | 0.282 | 0.280 | ||
| Support 4 (S4) | 0.275 |
